The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correction to Geyer et al., N Engl J Med 355(26):2733-2743 December 28, 2006.

Correction
PreviousPrevious
Volume 356:1487 April 5, 2007 Number 14
NextNext

Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

Since this article has no abstract, we have provided an extract of the first 100% of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Geyer, C. E.
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer . Table 3 (page 2741) should have included a footnote for Grade 4 adverse events: "A total of 13 grade 4 adverse events occurred among 10 (6%) of the patients receiving lapatinib plus capecitabine, and 16 grade 4 adverse events occurred among 11 (7%) of the patients receiving capecitabine alone. These differences are not significant." The table has been corrected on the Journal's Web site at www.nejm.org.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.